Genomic Health
LIFE, CHANGING.

Investor Contact:
investors@genomichealth.com

Corporate Fact Sheet

Key Facts

(as of 6.30.17)

Employees**: >845**

NASDAQ Ticker: **GHDX**

Q217 Revenue: **$85.5M**, 4% year-over-year increase

Cash and Cash Equivalents & Short-term Marketable Securities: **$109.8M**

Shares Used in Computing Basic Net Income Per Share (3 months): **34.4M**

Management

Kimberly Popovits,
Chairman of the Board,
Chief Executive Officer & President

G. Bradley Cole,
Chief Operating Officer &
Chief Financial Officer

Steven Shak, M.D.,
Co-Founder, Chief Scientific Officer

Frederic Pla, Ph.D.,
Chief Business & Product Development Officer

Jim Vaughn, R.Ph.,
Chief Commercial Officer

Phil Febbo, M.D.,
Chief Medical Officer

Laura Leber,
Chief Communications Officer

Kim McEachron,
Chief People Officer

Jason W. Radford,
Chief Legal Officer & Secretary

Ellen Beasley, Ph.D.,
Senior Vice President,
Products and Services R&D

Jon Cassel, Ph.D.,
Senior Vice President, Operations

Mike Vedda,
Senior Vice President, Information Technology, Chief Information Officer

Genomic Health, Inc. is the world's leading provider of genomic-based diagnostic tests that optimize cancer care, including addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX® gene expression tests that have been used to guide treatment decisions for more than 800,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests with the recently launched Oncotype SEQ® Liquid Select™ in lung cancer and collaboration with Epic Sciences to commercialize the Oncotype DX AR-V7 Nucleus Detect™ test this year. The company is based in Redwood City, California with international headquarters in Geneva, Switzerland.

- For more information, please visit www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

Business Model

Genomic Health's business model is based on the belief that clinically validated standardized genomic tests, in its Oncotype IQ portfolio of tests, provide valuable information for patients, physicians and payors.

- For over a decade, Genomic Health has delivered on the promise of precision medicine by providing personalized information based on a patient's unique biology to help ensure they receive the right treatment at the right time, allowing many to avoid unnecessary treatments and their side effects.
- Our tests are commercially available through our clinical reference laboratory located in Redwood City, California, which is accredited under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, and by the College of American Pathologists, or CAP. In addition, this laboratory is an ISO 15189:2012 Internationally-Recognized Accredited Laboratory for Clinical Testing.
- We now have prospective evidence from more than 63,000 patients demonstrating that the Oncotype DX Breast Recurrence Score® accurately predicts outcomes, including initial results from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx sponsored by the National Cancer Institute and published by *The New England Journal of Medicine*.
- We have a world-class commercial channel and successful track record in securing clinical guidelines and insurance coverage to provide physicians and patients with a trusted, single source for genomic tests; as well as online services that make it easy to interpret and share results with patients.
- Access to our tests enables personalized treatment decision-making and has saved the healthcare system more than 3.5 billion in the United States alone.[1]
- We will continue to expand the Oncotype IQ Genomic Intelligence Platform through our own internal research and development as well as strategic partnerships; all with the mission of delivering precision medicine to make cancer care smarter.

[1] Company estimation based on number of patients tested, chemotherapy reduction, health economics studies and treatment cost.

Investor Contact:
investors@genomichealth.com

Board of Directors

Julian Baker,
Managing Partner,
Lead Independent Director,
Baker Brothers Investments

Felix Baker, Ph.D.,
Managing Partner,
Baker Brothers Investments

Fred Cohen, M.D., D.Phil.,
Senior Advisor, TPG

Henry J. Fuchs, M.D.,
Executive Vice President &
Chief Medical Officer,
BioMarin Pharmaceutical Inc.

Ginger L. Graham,
Former President & Chief
Executive Officer, Amylin
Pharmaceuticals

Geoffrey M. Parker,
Chief Financial Officer and Senior
Vice President, Tricida, Inc.

Kimberly Popovits,
Chairman of the Board,
Chief Executive Officer &
President, Genomic Health, Inc.

Second Quarter 2017 Highlights

- Presented new results from a large, community-based, multi-center clinical validation study conducted at Kaiser Permanente at the American Urological Association (AUA) 2017 Annual Meeting. The results confirmed that the Oncotype DX GPS test is a strong independent predictor of prostate cancer-specific death and disease progression (metastases) at 10 years in men with localized prostate cancer.
- Data from two Oncotype DX GPS test analyses based on a prospective, multi-center, 1,200-patient study were also presented at AUA, including results that represent the first-ever prospective validation of a tissue-based molecular marker in prostate cancer. The second analysis, presented at AUA and published online in *Urology*, reinforced that the GPS test significantly increases use of and persistence on active surveillance.
- Initiated an early access Clinical Utility Program for select centers around the country in preparation for the commercial launch of the Oncotype DX AR-V7 Nucleus Detect™ test in collaboration with Epic Sciences.
- The 15th St. Gallen International Breast Cancer Conference Expert Panel published updated guidelines endorsing the Oncotype DX Breast Recurrence Score test for guiding treatment decisions on adjuvant chemotherapy in both node-negative and node-positive patients (up to three nodes).
- Breast Cancer Research and Treatment published positive five-year clinical outcomes results from the PlanB study led by the West German Study Group (WSG) in 93 centers across Germany. The study showed that women with Recurrence Score® results of 11 or less who were treated with hormonal therapy alone had excellent outcomes with 94 percent disease-free survival rates at five years despite having high-risk disease by traditional parameters.
- Presented results from eight studies across breast, prostate and kidney cancers that provide additional evidence of the value of Oncotype DX tests in predicting clinically meaningful endpoints and outcomes across cancer types at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.